Journal of Virology · 1998 · 130 citations · 28 references
Life SciencesBiologyMolecular BiologyDrug DiscoveryMolecular VirologyVirologyAntiretroviral TherapyAntiviral PharmacologyAntiviral TherapyViral AssemblyAntiviral TherapeuticsCombination TherapyPre-ribosomal Particle AssemblyProtease InhibitorsRibosomal TargetsViral Genome AssemblyVirus-like Particle Assembly
The recent development and use of protease inhibitors have demonstrated the essential role that combination therapy will play in the treatment of individuals infected with the human immunodeficiency virus type 1 (HIV-1). Past clinical experience suggests that due to the appearance of resistant HIV-1 variants, additional therapeutics will be required in the future. To identify new options for combination therapy, it is of paramount importance to pursue novel targets for drug development. Ribosomal frameshifting is one potential target that has not been fully explored. Data presented here demonstrate that small molecules can stimulate frameshifting, leading to an imbalance in the ratio of Gag to Gag-Pol and inhibiting HIV-1 replication at what appears to be the point of viral particle assembly. Thus, we propose that frameshifting represents a new target for the identification of novel anti-HIV-1 therapeutics.
28
Cold Spring Harbor Laboratory; Cold Spring Harbor, NY
T. Cavalier-Smith · FEBS Letters · 1980 · 6.3K citations · Full text
Complete nucleotide sequence of the AIDS virus, HTLV-III
Lee Ratner, William A. Haseltine, Roberto Patarca et al. · Nature · 1985 · 2.2K citations
Nucleotide sequence of the AIDS virus, LAV
Simon Wain–Hobson, P. Sonigo, Olivier Danos et al. · Cell · 1985 · 1.2K citations
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression
Tyler Jacks, Michael D. Power, Frank R. Masiarz et al. · Nature · 1988 · 947 citations
Genome organization and transactivation of the human immunodeficiency virus type 2
Mireille Guyader, Michael Emerman, P. Sonigo et al. · Nature · 1987 · 837 citations